-
Adrian Newman-Tancredi, PhD, DSc
… a drug candidate for treatment of levodopa-induced dyskinesia. Dr. Newman-Tancredi has published over 170 …
-
Oscar Samuel Gershanik, MD
… at the structural and molecular level, of levodopa-induced dyskinesias. He is also currently the president-elect of the …
-
Corey R. Hopkins, PhD
… activity of dopamine) as a novel therapy for L-DOPA-induced dyskinesias in Parkinson's disease, disabling involuntary …
-
Fasudil as a Novel Therapeutic for the Treatment of Parkinson's Disease
… levodopa efficacy or the emergence of levodopa induced dyskinesias, and whether fasudil protects neurons, or even … and its metabolites without impacting the magnitude of dyskinesias. Most importantly, fasudil significantly …
-
Michael J. Fox Foundation Awards $3 Million to Push Eight Industry Parkinson's Drug Development Projects Toward Commercialization
July 1, 2010
… Current Therapies Flibanserin in Levodopa-induced Dyskinesia: MPTP-lesioned Pre-clinical Model Jurgen Beck, … Receptor Antagonists for the Treatment of Levodopa-induced Dyskinesias in Parkinson’s Disease (Supplemental Award) …
-
Do Different Genders Experience Different Types of Parkinson’s?
October 19, 2020
… that women with Parkinson’s had a higher risk of developing dyskinesia (uncontrolled, involuntary movements) than men. … impairment therapy may enroll more men, and scales for dyskinesia may have more use in women than men earlier in …